Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Investor Day (September 2026)
13 slides from Novo Nordisk A/s Class B's investor day presentation, Sep 21, 2026
Slide 1: Diabetes
Diabetes Hong Chow CMD26 EVP, Product & Portfolio Strategy Martin Holst Lange CSO, EVP, Research & Development Capital Markets Day 21 September
Slide 2: Forward-looking statements
2 Diabetes Forward-looking statements Novo Nordisk’s statutory Annual Report 2025, Form 20-F, any quarterly financial reports, the materials displayed and other information provided (orally or in writing) at this Capital Markes Day as well as written information released, shown, or oral statements m
Slide 3: Diabetes remains one of the largest growing chronic disease markets
3 Diabetes Diabetes remains one of the largest growing chronic disease markets driven by a high disease burden and continued unmet need Diabetes prevalence is projected to increase globally Significant unmet need continues to persist despite substantial through 2050 therapeutic innovation and a high
Slide 4: Type 2 diabetes represents a large, progressive disease with high unmet need and low GLP-1 treatment rate
4 Diabetes Type 2 diabetes represents a large, progressive disease with high unmet need and low GLP-1 treatment rate 57% of adults with T2D are diagnosed, yet Addressing diabetes-related comorbidities will be critical to GLP-1s reach only 7% of these1 improving health outcomes as the diabetes popula
Slide 5: Ozempic pill launched under new brand with higher dose optionality
5 Diabetes Ozempic® pill, the world’s first oral GLP-1 approved for type 2 diabetes, is launched under new brand with higher dose optionality In PIONEER PLUS, Ozempic® pill demonstrated dose-dependent improvements in HbA1c Next steps for Ozempic® pill reduction and weight loss, supporting the potent
Slide 6: Novo aspires to be the lifelong partner of choice for people living with type 2 diabetes
6 Diabetes Novo aspires to be the lifelong partner of choice for people living with type 2 diabetes The partner of choice will increasingly be defined by clinical The diabetes pipeline is positioned to address evolving patient outcomes and treatment experiences beyond HbA1c needs beyond HbA1c over t
Slide 7: Novo is uniquely positioned to sustain leadership in diabetes
7 Diabetes Novo is uniquely positioned to sustain leadership in diabetes, aiming to drive expansion of novel treatments Scientific depth Portfolio breadth Scalable operation Insulin Combo Incretin Global discovery, development and >100 years of diabetes leadership manufacturing network Pioneers in G
Slide 8: CagriSema delivers attractive HbA1c lowering and meaningful weight loss in T2D
8 Diabetes CagriSema delivers attractive HbA1c lowering and meaningful weight loss of more than 14% in T2D Reduction in kidney disease progression Superior HbA1c control 24% 1.8-2.3%-p reduction in major kidney disease events1 reduction in HbA1c Best in class CV protection Building on Combining the
Slide 9: REIMAGINE demonstrated CagriSema delivers a highly competitive profile in T2D
9 Diabetes REIMAGINE 5 demonstrated that CagriSema delivers a highly competitive profile for patients living with T2D, even at low doses In REIMAGINE 51, CagriSema 1.0/1.0 mg demonstrated superior weight loss Next steps on CagriSema in T2D and non-inferior HbA1c reduction vs tirzepatide 5 mg Mean ba
Slide 10: CagriSema significantly reduced pain among patients with T2D and painful diabetic peripheral neuropathy
10 Diabetes CagriSema significantly reduced pain among patients with T2D and painful diabetic peripheral neuropathy Painful diabetic peripheral neuropathy is Phase 21 demonstrated robust & clinically Additional benefits and next steps for a serious & disabling complication of T2D meaningful pain red
Slide 11: Zenagamtide demonstrated significant weight loss and HbA1c reduction in T2D
11 Diabetes In a 36-week phase 2 trial, zenagamtide demonstrated significant weight loss and HbA1c reduction in a T2D population Maximum weight loss achieved1 Maximum HbA1c reduction achieved1 Zenagamtide in T2D has entered phase 3 Mean baseline bodyweight: 99.2 kg Mean baseline HbA1c: 7.8% with the
Slide 12: Advancing diabetes care requires new mechanisms of action, modalities and combinations
12 Diabetes Advancing diabetes care beyond strong HbA1c control requires new mechanisms of action, modalities and combinations The early research engine is running at full speed, with 4 first human doses planned for 2026 Disease Novel Asset Phase Modality Weight loss DRC Convenience Tolerability mod
Slide 13: Diabetes remains a large, underpenetrated and durable long-term growth opportunity
13 Diabetes 1 2 3 Diabetes remains a large, underpenetrated Differentiated profiles of CagriSema and Novo is uniquely positioned to lead the next and durable long-term growth opportunity zenagamtide (sc/oral) extend the future era of diabetes innovation through scientific treatment paradigm toward b